Rockville biopharma’s ADHD drug emerges from the clinic with good news

The results come less than two months after the FDA rejected the company’s application to market the treatment to children and adolescents.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.